Alterity Therapeutics Ltd. Sponsored ADR Stock

$1.11

5.56% yesterday

Nasdaq, Nov 15, 08:37 pm CET

ISIN

US02155X1063

Symbol

ATHE

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Overview Dividends Analysts Charts News Strategies

Alterity Therapeutics Ltd. Sponsored ADR Stock price

$1.11

-9.15 89.22% 5Y

Nasdaq, Closing price Fri, Nov 15 2024

-0.07 5.56%

ISIN

US02155X1063

Symbol

ATHE

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Key metrics

Market capitalization	$9.80m
Enterprise Value	$1.47m
P/E (TTM) P/E ratio	negative
EV/FCF (TTM) EV/FCF	negative
P/B ratio (TTM) P/B ratio	1.05
Revenue (TTM) Revenue	$0.00
EBIT (operating result TTM) EBIT	$-15.50m
Free Cash Flow (TTM) Free Cash Flow	$-8.30m
EPS (TTM) EPS	$-2.06
P/E forward	negative
P/S forward	1.64
EV/Sales forward	0.32
Short interest	0.04%

As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.

Get Started for Free Today

Alterity Therapeutics Ltd. Sponsored ADR Stock Analysis

Unlock Scores for Free

??

1 Analyst has issued a forecast Alterity Therapeutics Ltd. Sponsored ADR:

1x Buy

100%

More details on Analyst Estimates Including Price Targets

1 Analyst has issued a forecast Alterity Therapeutics Ltd. Sponsored ADR:

Buy

100%

Analyst Estimates with Stock Price Targets

Financial data from Alterity Therapeutics Ltd. Sponsored ADR

Income Statement P&L | Balance Sheet | Cash Flow

TTM Annually

Jun '24		+/- %
Revenue	- -	- 100%
- Direct Costs	0.10 0.10	43% 43% -
Gross Profit	-0.10 -0.10	43% 43% -
- Selling and Administrative Expenses	3.07 3.07	11% 11% -
- Research and Development Expense	12 12	38% 38% -
EBITDA	-15 -15	24% 24% -
- Depreciation and Amortization	0.10 0.10	43% 43% -
EBIT (Operating Income) EBIT	-15 -15	24% 24% -
Net Profit	-13 -13	35% 35% -

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Alterity Therapeutics Ltd. Sponsored ADR Stock News

Neutral

GlobeNewsWire

●

4 days ago

Alterity Therapeutics Announces Presentation on Tracking the Progression of Multiple System Atrophy at International Symposium

MELBOURNE, Australia and SAN FRANCISCO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced the presentation of data from Alterity's Biomarkers of progression in Multiple System Atrophy (bioMUSE) natural history ...

Neutral

GlobeNewsWire

●

10 days ago

Alterity Therapeutics Announces New Publication Describing Novel Mechanism of Action for ATH434

– Peer-Reviewed Publication Describes How ATH434 Uniquely Targets Excess Iron – – Peer-Reviewed Publication Describes How ATH434 Uniquely Targets Excess Iron –

Neutral

GlobeNewsWire

●

16 days ago

Appendix 4C – Q1 FY25 Quarterly Cash Flow Report

Highlights Topline data for ATH434-201 randomized, double-blind Phase 2 clinical trial on track for release in January 2025 Positive interim data reported from ATH434-202 Phase 2 clinical trial showing the potential for ATH434 to modify disease progression in Multiple System Atrophy Multiple data presentations at the International Congress of Parkinson's Disease and Movement Disorders® (MDS) Ap...

More Alterity Therapeutics Ltd. Sponsored ADR News

Company Profile

Alterity Therapeutics Ltd. engages in the development of therapeutic drugs designed to treat the underlying causes of degeneration of the brain as the aging process progresses. It focuses on Parkinson's movement disorders, Alzheimer's disease, Huntington disease, and other neurodegenerative disorders. The company was founded by Geoffrey Paul Kempler on November 11, 1997 and is headquartered in Melbourne, Australia.

Head office	Australia
CEO	David Stamler
Employees	10
Founded	1997
Website	www.alteritytherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now